Cargando…

Advanced Pharmacotherapy Evidenced by Pathogenesis of Autism Spectrum Disorder

In clinical practice, pharmacological treatment is mostly focused on behavioral symptoms in everyday life. Nevertheless, persistent effort continues to develop medication for causal treatment. Recent changes in diagnostic criteria from Diagnostic and Statistical Manual of Mental Disorders, 4th editi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yeon Jung, Oh, Soo Hyun, Park, Chanmin, Hong, Minha, Lee, Ah Rah, Yoo, Hee Jeong, Shin, Chan Young, Cheon, Keun-Ah, Bahn, Geon Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022762/
https://www.ncbi.nlm.nih.gov/pubmed/24851117
http://dx.doi.org/10.9758/cpn.2014.12.1.19
_version_ 1782316463872278528
author Lee, Yeon Jung
Oh, Soo Hyun
Park, Chanmin
Hong, Minha
Lee, Ah Rah
Yoo, Hee Jeong
Shin, Chan Young
Cheon, Keun-Ah
Bahn, Geon Ho
author_facet Lee, Yeon Jung
Oh, Soo Hyun
Park, Chanmin
Hong, Minha
Lee, Ah Rah
Yoo, Hee Jeong
Shin, Chan Young
Cheon, Keun-Ah
Bahn, Geon Ho
author_sort Lee, Yeon Jung
collection PubMed
description In clinical practice, pharmacological treatment is mostly focused on behavioral symptoms in everyday life. Nevertheless, persistent effort continues to develop medication for causal treatment. Recent changes in diagnostic criteria from Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) to DSM-5 would affect not only diagnosing approaches, but also therapeutic approaches. Because previous pervasive developmental disorders have been integrated into a single entity, the autism spectrum disorder (ASD), we have to prepare for what medications are valuable for the ASD. In this article, we reviewed the following etiological treatment: acetylcholine and glutamate related medicine; amino acid medicine such as secretin, endogenous opioid, and oxytocin; complementary and alternative medicine such as chelating agents, vitamins, and omega-3; promising drugs related to the scope of pharmacogenetics currently under study.
format Online
Article
Text
id pubmed-4022762
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Korean College of Neuropsychopharmacology
record_format MEDLINE/PubMed
spelling pubmed-40227622014-05-21 Advanced Pharmacotherapy Evidenced by Pathogenesis of Autism Spectrum Disorder Lee, Yeon Jung Oh, Soo Hyun Park, Chanmin Hong, Minha Lee, Ah Rah Yoo, Hee Jeong Shin, Chan Young Cheon, Keun-Ah Bahn, Geon Ho Clin Psychopharmacol Neurosci Review In clinical practice, pharmacological treatment is mostly focused on behavioral symptoms in everyday life. Nevertheless, persistent effort continues to develop medication for causal treatment. Recent changes in diagnostic criteria from Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) to DSM-5 would affect not only diagnosing approaches, but also therapeutic approaches. Because previous pervasive developmental disorders have been integrated into a single entity, the autism spectrum disorder (ASD), we have to prepare for what medications are valuable for the ASD. In this article, we reviewed the following etiological treatment: acetylcholine and glutamate related medicine; amino acid medicine such as secretin, endogenous opioid, and oxytocin; complementary and alternative medicine such as chelating agents, vitamins, and omega-3; promising drugs related to the scope of pharmacogenetics currently under study. Korean College of Neuropsychopharmacology 2014-04 2014-04-24 /pmc/articles/PMC4022762/ /pubmed/24851117 http://dx.doi.org/10.9758/cpn.2014.12.1.19 Text en Copyright© 2014, Korean College of Neuropsychopharmacology http://creativecommons.org/licenses/by-nc/3.0/ This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Lee, Yeon Jung
Oh, Soo Hyun
Park, Chanmin
Hong, Minha
Lee, Ah Rah
Yoo, Hee Jeong
Shin, Chan Young
Cheon, Keun-Ah
Bahn, Geon Ho
Advanced Pharmacotherapy Evidenced by Pathogenesis of Autism Spectrum Disorder
title Advanced Pharmacotherapy Evidenced by Pathogenesis of Autism Spectrum Disorder
title_full Advanced Pharmacotherapy Evidenced by Pathogenesis of Autism Spectrum Disorder
title_fullStr Advanced Pharmacotherapy Evidenced by Pathogenesis of Autism Spectrum Disorder
title_full_unstemmed Advanced Pharmacotherapy Evidenced by Pathogenesis of Autism Spectrum Disorder
title_short Advanced Pharmacotherapy Evidenced by Pathogenesis of Autism Spectrum Disorder
title_sort advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022762/
https://www.ncbi.nlm.nih.gov/pubmed/24851117
http://dx.doi.org/10.9758/cpn.2014.12.1.19
work_keys_str_mv AT leeyeonjung advancedpharmacotherapyevidencedbypathogenesisofautismspectrumdisorder
AT ohsoohyun advancedpharmacotherapyevidencedbypathogenesisofautismspectrumdisorder
AT parkchanmin advancedpharmacotherapyevidencedbypathogenesisofautismspectrumdisorder
AT hongminha advancedpharmacotherapyevidencedbypathogenesisofautismspectrumdisorder
AT leeahrah advancedpharmacotherapyevidencedbypathogenesisofautismspectrumdisorder
AT yooheejeong advancedpharmacotherapyevidencedbypathogenesisofautismspectrumdisorder
AT shinchanyoung advancedpharmacotherapyevidencedbypathogenesisofautismspectrumdisorder
AT cheonkeunah advancedpharmacotherapyevidencedbypathogenesisofautismspectrumdisorder
AT bahngeonho advancedpharmacotherapyevidencedbypathogenesisofautismspectrumdisorder